Curi Bio Announced 2020 Tibbetts Award Winner by US Small Business Administration
Curi Bio is honored to be announced a 2020 Tibbetts Award Winner by the U.S. Small Business Administration! This award recognizes our critical role in successfully driving high-tech innovation within the U.S. with our next-generation human stem cell platforms.
SEATTLE—Curi Bio, a leading developer of human stem cell-based biotechnology products and services for drug discovery and development, announced today that it was selected as a winner of the 2020 Tibbetts Award from the US Small Business Administration (SBA). The Tibbetts Award is given to outstanding entities for the exceptional successes achieved through the SBA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Curi Bio is one of 38 companies, seven organizations, and 14 individuals selected as Tibbetts Award winners in successfully driving high-tech innovation in the U.S. Past awardees include 23andMe, Qualcomm, Symantec, and Broadcom.
Named after Roland Tibbetts, the acknowledged founder of the SBIR program, the prestigious Tibbetts Awards recognize companies, organizations, and individuals that exemplify the very best in SBIR/STTR achievements. Awardees are recognized for their critical roles in research and development, successfully driving innovation, and creating new jobs through the SBIR and STTR programs. Recipients are traditionally invited to the White House in Washington, D.C. to attend the Tibbetts Awards Ceremony in person.
“For nearly four decades, the SBIR and STTR programs have been assisting small businesses with launching ideas from conception to market. The Tibbetts Awards highlight our nation’s next generation of competitive creators who help push the U.S. economy into the future,” said SBA Administrator Jovita Carranza.
Since its founding in 2015, Curi Bio has received $5.3 million in total non-dilutive SBIR funding. Curi will also receive an additional $1.5 million upon successful completion of scientific milestones in 2021. The company has used this funding to rapidly develop its world-class stem cell platforms for use in drug discovery and development. The company credits not only project funding, but programmatic support from the US Department of Human Health and Services (HHS) as a vital and invaluable resource for successful commercialization, as well as in the company’s ability to build a strong, diverse, and highly capable technical workforce for the United States.
“Receiving the Tibbetts Award is an incredible honor for our team,” said Dr. Nicholas Geisse, PhD, Chief Science Officer of Curi Bio. “This award validates Curi’s technologies in making the drug development process safer and more efficient as we help tackle some of the world’s most devastating diseases. As a rapidly growing startup, we would like to thank the SBA, NIH, and SBIR/STTR programs for granting us the seed funding necessary for research and development of our cutting-edge technologies and accelerate the discovery of new medicines.”
For the full U.S. SBA press release on 2020 Tibbetts Awardees, please click here.
To learn more about Curi Bio’s 2020 Tibbetts Award, please click here.
About Curi Bio
Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell maturation platforms and services enable scientists to build more mature and predictive human stem cell-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. Drug developers can access an integrated preclinical discovery platform with highly predictive human stem cell models to generate clinically-relevant data. Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.
For more information, please visit www.curibio.com.